Lung Cancer News

Among people who have never smoked, the risk for lung cancer was more than twice as high among those with COPD, as compared with those without COPD, according to a Korean study.

Two treatment regimens showed efficacy as second-line therapy for older adults with non-small cell lung cancer, according to results of separate studies published in Cancer.

A novel blood test accurately detected more than 50 types of cancer with a specificity of 99.3%, according to results of the prospective Circulating Cell-free Genome Atlas study published in Annals of Oncology.

The FDA approved durvalumab in combination with standard chemotherapy as first-line treatment of adults with extensive-stage small cell lung cancer.

Risk for infection with SARS-CoV-2 — the novel coronavirus that causes COVID-19 — appeared more than twice as high among individuals with cancer than the general population, according to an analysis of data from a tertiary care hospital in Wuhan, China.

The novel HER2-targeted antibody-drug conjugate fam-trastuzumab deruxtecan-nxki appeared active in a cohort of patients with various heavily pretreated HER2-expressing or HER2-mutant solid tumors, according to results of a dose-expansion study published in Cancer Discovery.

The addition of durvalumab to a choice of standard-of-care first-line chemotherapies conferred a sustained OS benefit for patients with extensive-stage small cell lung cancer, according to topline results of a randomized phase 3 trial released by the agent’s manufacturer.

The FDA granted breakthrough therapy designation to JNJ-6372 for the treatment of certain patients with metastatic non-small cell lung cancer, according to the agent’s manufacturer.

Healio Pulmonology has you covered. The Editors have compiled a list of popular articles posted on Healio Pulmonology in February.

International Association for the Study of Lung Cancer will name its Translational Research Lectureship Award after Fred R. Hirsch, MD, PhD.